top of page
Browse by category
Search
Innovent’s Mazdutide 9mg accepted for review by China’s NMPA
Innovent Biologics’ supplementary application for the 9 mg dosage of mazdutide, an innovative glucagon (GCG)/ glucagon-like peptide-1 (GLP-1) dual receptor agonist, for the long-term weight management in adults with moderate to severe obesity has been accepted for review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). This application of mazdutide 9 mg aims to address a pressing unmet clinical need in China by offering a hig
Mazdutide 9 mg achieves up to 20.1% weight loss as GLORY-2 Study meets primary and all key secondary endpoints
Outcomes from the Phase 3 clinical trial of mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with obesity (GLORY-2) has met the primary endpoints and all key secondary endpoints. Innovent Biologics plans to submit the new drug application (NDA) of mazdutide 9 mg for weight management to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) in the near term. GLORY-2 is
Innovent receives FDA Approval for IND application of oral GLP-1R agonist IBI3032
Innovent Biologics has announced the FDA has approved the investigational new drug (IND) application to initiate a Phase 1 clinical trial...
First dual GCG/GLP-1ra gains approval from China’s NMPA for chronic weight management
China's National Medical Products Administration (NMPA) has approved Innovent Biologics’ mazdutide, a first-in-class dual glucagon...
First participant dosed GLORY-OSA trial of mazdutide in China
The first participant has been successfully dosed in a Phase 3 clinical trial (GLORY-OSA) of mazdutide, a dual glucagon (GCG) and...
GLORY-1 outcomes shows positive results for mazdutide - a dual glucagon GCG-1/GLP-1 receptor agonist
The results from GLORY-1 - a Phase 3 clinical study of mazdutide - a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor...
Innovent’s DREAMS-1 trial of mazdutide GLP-1R and GCGR dual agonist meets study endpoints
Innovent Biologics’ Phase 3 clinical trial (DREAMS-1) of mazdutide a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor...
Innovent’s GLORY-1 trial assessing mazdutide meets its primary endpoints
Innovent Biologics has announced the key results of the first Phase 3 clinical trial of mazdutide in Chinese adults with overweight or...
Mazdutide superior compared with dulaglutide for glycaemic control, weight loss, blood lipid and pressure
Innovent Biologics’ Phase 3 clinical trial (DREAMS-2) of mazdutide (IBI362) in Chinese subjects with type 2 diabetes (T2D) has met its...
Innovent's mazdutide accepted by China’s NMPA for chronic weight management
Innovent Biologics’ New Drug Application (NDA) for mazdutide (Innovent R&D code: IBI362), a glucagon-like peptide-1 receptor (GLP-1R) and...
Browse by tag
bottom of page